Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VAD044 Part I · 1 trial · 1 indication
Type and severity of Adverse Events (AEs)
Type and severity of Adverse Events (AEs)
| Arm | Type | Description |
|---|---|---|
| 30 mg | EXPERIMENTAL | 30 mg VAD044 |
| 40 mg | EXPERIMENTAL | 40 mg VAD044 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| VAD044 Part I | DRUG | capsules to be taken once daily for 12 weeks |
| VAD044 Part II | DRUG | capsules to be taken once daily for 36 months |
For Part I of the study: Inclusion Criteria: * Diagnosis of HHT by the Curaçao criteria * Several epistaxis/week * Anaemia * COVID-19 vaccination or positive COVID-19 antibody test * Patient has given written informed consent to participate in Part I Exclusion Criteria: * Type 1 diabetes or unco...
VAD044 is an investigational small molecule being studied for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder characterized by abnormal blood vessel formation. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
VAD044 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for Hereditary Hemorrhagic Telangiectasia (HHT).
VAD044 is currently in Phase 1 clinical development. It is an investigational drug being studied for Hereditary Hemorrhagic Telangiectasia (HHT) and has not yet received regulatory approval. The ongoing Phase 1 trial is active but not recruiting participants.
VAD044 is being evaluated in a Phase 1 clinical trial with the identifier NCT05406362, titled 'Assess Safety and Efficacy of VAD044 in HHT Patients.' This randomized, double-blind, placebo-controlled trial is enrolling 75 participants aged 18 years and older with Hereditary Hemorrhagic Telangiectasia (HHT) across the United States, Belgium, France, Italy, Netherlands, and Spain.
No, VAD044 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT). The drug is being studied for safety and efficacy but has not yet completed the clinical development process required for regulatory approval.